Ginkgo Bioworks Holdings, Inc. (DNA) ended the recent trading session at $15.12, demonstrating a -4.49% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a ...

Ginkgo Bioworks Holdings, Inc. (DNA) has been on a downward spiral lately with significant selling pressure. After declining 28.8% over the past four weeks, the stock looks well positioned for a trend ...

Ginkgo Bioworks Holdings, Inc. (DNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

Ginkgo's Class A Common Stock continues to trade on the NYSE BOSTON, May 13, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (DNA) (NYSE: DNA, "Ginkgo" or the "Company"), which is building the ...

Collaboration enhanced the productivity of Biogen's AAV production platform to help accelerate efforts to bring novel gene therapies to patients worldwide BOSTON, Jan. 4, 2024 /PRNewswire/ -- Ginkgo ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) stands against other best ...

Ginkgo Bioworks (NYSE:DNA – Free Report) had its target price lifted by BTIG Research from $6.00 to $9.00 in a report issued on Monday morning,Benzinga reports. The firm currently has a sell rating on ...

We recently published an article titled Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential. In this article, we are going to take a look at where Ginkgo Bioworks Holdings, Inc.

$1.633 billion in proceeds from the business combination represents the largest-ever biotechnology go-public transaction. Investors were led by Baillie Gifford, Putnam Investments, and funds and ...